# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CURRENT REPORT	
Pursuant to Section 13 or 15(d)	
f the Securities Exchange Act of 1934	
January 26, 2016	
Date of Report	
TAPIMMUNE INC.	
APIMMUNE INC.	45-4497941 (IRS Employer

50 N. Laura Street, Suite 2500 Jacksonville, FL (Address of principal executive offices)

Nevada (State or other jurisdiction of incorporation)

> (206) 504-7278 Registrant's telephone number, including area code

\$N/A\$ (Former name or former address, if changed since last report)

ck the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following isions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 27, 2016, TapImmune Inc. (the "Company"), announced that Frederick G. Wasserman, age 60, of Pennington, New Jersey, has been appointed to the Board of Directors of the Company. A copy of the press release is attached to this Report as Exhibit 99.1. Mr. Wasserman's appointment was effective on July 26, 2016.

Mr. Wasserman is a business executive with over 35 years of business experience, having served at various companies in roles including Chief Executive Officer, President, Chief Operating Officer and Chief Financial Officer. He is currently the President of FGW Partners LLC, Pennington, NJ, where he has been employed since 2007. He currently serves on the boards of directors of several public companies.

Mr. Wasserman was employed as a certified public accountant from 1976 to 1989. He earned a Bachelor of Science degree from The Wharton School at The University of Pennsylvania in 1976.

Pursuant to the Director Compensation Plan previously approved by the Board of Directors, in connection with his appointment to the Board Mr. Wasserman was granted an option to purchase 150,000 shares of the common stock of the Company under the 2014 Omnibus Stock Ownership Plan, at a price equal to the closing price of the common stock on the date of his appointment, with such options to vest in in equal monthly installments over the following 24 months.

# Item 9.01 Financial Statements and Exhibits.

Exhibit 99.1 Press release issued on January 27, 2016

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### TAPIMMUNE INC.

Date: January 27, 2016 By: /s/ Glynn Wilson

Name: Glynn Wilson Title: Chairman and CEO

# TapImmune Appoints Frederick G. Wasserman to its Board of Directors

Accomplished Financial Director & CFO of Public Companies

PR Newswire

JACKSONVILLE, Florida, January 27, 2016

JACKSONVILLE, Florida, January 27, 2016 /PRNewswire/ —

<u>TapImmune Inc.</u> (OTCMKTS: TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, is pleased to announce the appointment of Frederick G. Wasserman to its Board as an Independent Director.

Frederick (Rick) is an accomplished Board Director with 35 years of business experience. He has served during his career as President, COO and CFO of entrepreneurial, middle-market companies. Rick has a strong financial background which he has successfully focused on all aspects of company operations including cash flow, profitability and equity valuation. He has served as a member of Audit and Corporate Governance Committees for public companies in the U.S. and Europe. In his role as President of FGW Partners LLC, Pennington, New Jersey, he has assisted small and micro-cap companies at transitional points in their evolutions. This has included focus on corporate governance, investment analysis and liquidity management, as well as general financial and operational issues.

Rick was a Certified Public Accountant who held staff positions through Audit Manager for three accounting firms. He has a B.S. in Economics from the Wharton School, University of Pennsylvania, PA.

Dr. Glynn Wilson, Chairman & CEO of TapImmune, stated, "We welcome Rick to the TapImmune Board of Directors. His strong financial background and success in working as an Officer or as a Board member of a variety of entrepreneurial public companies will be a significant asset to TapImmune in the next phase of our Company's growth".

# **About TapImmune Inc.**

TapImmune Inc. is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastatic disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at <a href="http://www.tapimmune.com">http://www.tapimmune.com</a> for details.

#### Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at <a href="http://www.sec.gov">http://www.sec.gov</a>. The Company assumes no obligation to update the forward-looking statements.

# **CONTACTS:**

**TapImmune Inc.,**Glynn Wilson, Ph.D.
Chairman & CEO
+1-(866)-359-7541
SOURCE TapImmune Inc.

Copyright © 2016 PR Newswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.